Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Kaposi's sarcoma Stories

2014-02-18 23:26:46

MarketResearchReports.Biz announces addition of new report “AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014” to its database. Visit: http://www.marketresearchreports.biz/analysis/187350. Albany, NY (PRWEB) February 18, 2014 Global Markets Directs, 'AIDS Related Kaposi's Sarcoma Pipeline Review, H1 2014', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for AIDS Related Kaposi's...

2013-11-18 12:28:17

COLORADO SPRINGS, Colo., Nov. 18, 2013 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, highlights two articles validating Cannabis Science's research premise addressing the utility of cannabinoid-mediated viral suppression of HIV's replication cycle: an independent article in the July 2013 issue of A&U magazine, entitled "CB Breaker: Cannabinoids May Be Effective In Treating HIV, Not Just...

Detecting Disease Using Smartphone Accessory
2013-06-04 12:34:27

The Optical Society New plug-in optical sensor could be used for in-the-field diagnosis of Kaposi's sarcoma, a cancer linked to AIDS As antiretroviral drugs that treat HIV have become more commonplace, the incidence of Kaposi's sarcoma, a type of cancer linked to AIDS, has decreased in the United States. The disease, however, remains prevalent in sub-Saharan Africa, where poor access to medical care and lab tests only compound the problem. Now, Cornell University engineers have created...

2013-04-26 12:27:20

Therapeutic Discovery Program initiated in the Netherlands, executed along U.S. guidelines for regulatory submission AMSTERDAM, April 26, 2013 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS) announced today the initiation of preclinical development characterization of CS-TATI-I following the execution of contractual retention of vendor labs located in the Amsterdam Life Science Cluster. Under the direction of Richard Ogden, PhD, Chief Scientific Officer, and Christopher...

2013-01-31 08:30:56

COLORADO SPRINGS, Colo., Jan. 31, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASD OTC: CBIS) announced today its Corporate Operational Guidance for 2013, highlighting a strategic action plan to "bring to market" innovative, cannabinoid-based, life-saving, anti-cancer drugs. The Company anticipates releasing a variety of cannabinoid-based treatments that already show great promise in fighting HIV-related illnesses like Kaposi's Sarcoma that is on the rise due to the developing resistance to...

2012-11-12 12:26:33

COLORADO SPRINGS, Colo., Nov. 12, 2012 /PRNewswire/ -- Cannabis Science, Inc., (CBIS) announces Harvard Medical School releases peer-reviewed study in the Genes & Cancer Journal strongly suggesting that Cannabidiol inhibits growth and induces programmed cell death in Kaposi Sarcoma-associated Herpesvirus-Infected Endothelium. These results from the study at Harvard Medical School support Cannabis Science's approach to the development of CS-TATI-1 to inhibit Kaposi Sarcoma. Cannabis...

2012-03-12 21:22:42

Research has implications for treating and preventing cancers caused by viruses New research from the Trudeau Institute addresses how the human body controls gamma-herpesviruses, a class of viruses thought to cause a variety of cancers. The study, carried out in the laboratory of Dr. Marcia Blackman, awaits publication in The Journal of Immunology. Led by postdoctoral fellow Mike Freeman, with assistance from other laboratory colleagues, the study describes the role of white blood cells in...

2012-02-23 07:00:00

SOUDERTON, Pa., Feb. 23, 2012 /PRNewswire/ -- Galen, a Northern Ireland Pharmaceutical company, has acquired the chemotherapy agent, DaunoXome(®) (daunorubicin citrate liposome injection) from Gilead Sciences, Inc. Galen US, Inc., a wholly owned subsidiary of Galen Ltd., will market DaunoXome(®) in the United States. To view the multimedia assets associated with this release, please click:...

2012-01-17 12:00:00

By the National Cancer Institute BETHESDA, Md., Jan. 17, 2012 /PRNewswire-USNewswire/ -- Racial and ethnic minorities in America have been hit harder than white Americans by the HIV/AIDS epidemic-they make up about one-third of the population but two-thirds of all cases. In 2009, African Americans made up 14 percent of the population but accounted for 44 percent of all new HIV infections. And Hispanics made up 16 percent of the population but 20 percent of new cases in 2009. (Logo:...

2011-12-14 19:44:17

Human tumor viruses contribute to 15-20% of human cancers worldwide. Kaposi's sarcoma herpesvirus (KSHV) is an etiological agent for Kaposi's sarcoma (KS) and two other rare lymphoproliferative malignancies. KS is the most common cancer in HIV-infected untreated individuals and remains a primary cause of cancer deaths in many subequatorial African countries as a result of the AIDS pandemic. Researchers at the Institute of Biotechnology and Research Programs Unit (Genome-Scale Biology) at the...


Latest Kaposi's sarcoma Reference Libraries

0_336928514f8c16d00d00e956be85245d
2011-02-17 15:06:48

Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...

More Articles (1 articles) »